The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary phase 1/1b dose expansion results of the bifunctional EGFR/TGFß inhibitor ficerafusp alfa (BCA101) with pembrolizumab in patients with squamous cell carcinoma of the anal canal.
 
Van Morris
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Incyte; Novartis; Regeneron; Scandion Oncology
Research Funding - Apollo Therapeutics (Inst); Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Redx Pharma (Inst); Sumitomo Pharma Oncology (Inst)
 
Brandon Huffman
Consulting or Advisory Role - Loxo/Lilly
 
Cathy Eng
Consulting or Advisory Role - Abbvie; Amgen (I); California Institute for Regenerative Medicine (CIRM) (I); Hookipa Biotech; IgM Biosciences (I); Merck Serono; Pfizer; Seagen; Taiho Oncology (I); Takeda
Research Funding - Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Takeda
 
Rita Dalal
Employment - Bicara Therapeutics
Stock and Other Ownership Interests - Alkermes; Bicara Therapeutics
Patents, Royalties, Other Intellectual Property - Mural Oncology
 
Rachel Salazar
Employment - Bicara Therapeutics
Stock and Other Ownership Interests - Bicara Therapeutics
Travel, Accommodations, Expenses - Bicara Therapeutics
 
David Bohr
Employment - Bicara Therapeutics
Stock and Other Ownership Interests - Bicara Therapeutics; Bristol Myers Squibb Foundation; Gilead Sciences; Johnson & Johnson/Janssen
 
Kaitlin Morton
Employment - Bicara Therapeutics
Stock and Other Ownership Interests - Bicara Therapeutics
 
Philippe Bedard
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); LegoChem Biosciences (Inst); LegoChem Biosciences (Inst); Lilly (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - Janssen Oncology; Lilly; Repare Therapeutics; Roche/Genentech; Seagen; Zymeworks